Early diagnosis and targeted treatment against heart attacks

Over 8 million people die from heart attacks (myocardial infarction) each year. This is because clinical diagnostic technologies
do not identify high-risk patients, and current therapeutics cannot prevent infarction.

Mabimmune prevents heart attacks through early diagnosis and targeted treatment. PlaqueVision is a human-antibodybased
imaging agent that identifies high-risk patients by locating life-threatening atherosclerotic plaques. FlowMab is a human-antibody-based therapy that stabilizes life-threatening plaques to prevent infarction. PlaqueVision and FlowMab will
be combined into a clinical package to: 1) identify high-risk patients, 2) locate unstable atherosclerotic plaques, and
3) stabilize life-threatening plaques to prevent heart attacks.

Mabimmune’s best-in-class human-antibody-based agents target a patented portfolio of heart-attack triggering biomolecules.
An expert medical team with over 50 years of biopharmaceutical experience will direct PlaqueVision and FlowMab through clinical trials and into the CHF 87.7 billion market.

Mabimmune Diagnostics is a spin-off from Universität Zürich. Teamleader is Chad Brokopp.

The jury of >>venture>> says about Mabimmune: "Mabimmune Diagnostics’ innovation has very high potential and addresses a clear need in the market for prevention of myocardial infarctions and strokes. The team comprises several biomedical experts with a strong track record in biopharmaceutical start-ups."